Eli Lilly and Company: Urinary Bladder Neoplasms trials
The registry lists 14 Urinary Bladder Neoplasms studies with Eli Lilly and Company as lead sponsor. 5 are open to participants now and 4 have results posted.
Phase 1 5Phase 2 5Phase 3 3No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerNot yet recruitingNCT07827612Phase 2
- Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid TumorsAvailableNCT07675057
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary TractRecruitingNCT07218380Phase 3
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Phase 1
- FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3RecruitingNCT05614739Phase 1
- A Study of LY3076226 in Participants With Advanced or Metastatic CancerCompletedNCT02529553Phase 1Results posted
- A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract CancerCompletedNCT02443324Phase 1Results posted
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial CancerCompletedNCT02426125Phase 3Results posted
- Instillation of Gemcitabine in Patients With Superficial Bladder CancerTerminatedNCT00191477Phase 3Results posted
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
- Intravesical Chemotherapy Treatment of Superficial Bladder CancerCompletedNCT00491114Phase 2
- Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder CancerCompletedNCT00490880Phase 2
- A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the UrotheliumCompletedNCT00035061Phase 2
- A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00034593Phase 2